FDA requires monitoring of long-term clinical outcomes for robotic surgery in breast cancer

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

FDA issued a safety communication Aug. 20 that included new recommendations for IRBs and investigators studying robotically-assisted surgical devices for use in mastectomy procedures or in the prevention or treatment of breast cancer.

To access this subscriber-only content please log in or renew your subscription.

Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Login